Table 1.
Clinical studies on combined LRT and MRT for HCC
| Study [reference] | No. of patients | Comparative design | Treatment modalities | Timing of MTA | Tumor extent (BCLC stage) | Baseline liver function (Child-Pugh class) | Primary endpoint |
|---|---|---|---|---|---|---|---|
| Kudo et al. [27] | 458 | Yes | Sorafenib + TACE vs. TACE | Sequential | B | A | TTP |
| Lencioni et al. [SPACE)[28] | 307 | Yes | DEB-TACE + sorafenib vs. DEB-TACE + placebo | Continuous | B | A | TTP |
| Martin et al. [29] | 150 | Yes | Sorafenib + DEB-TACE vs. DEB-TACE | NA | B, C (ratio, NA) | B in 31% of combination group; B in 39% of DEB-TACE | OS |
| Sansonno et al. [30] | 80 | Yes | Sorafenib + TACE vs. TACE | Sequential | B | A | TTP |
| Chung et al. [START] [31] | 63 (safety), 50 (efficacy) | No | Sorafenib + TACE | Sequential | A, 17.3% B, 80.9% C, 1.9% | A, 91.6% | Tumor response |
| Park et al. (COTSUN Korea)[32] | 50 | No | Sorafenib + TACE | Interrupted | B, 82% C, 18% | A, 89% B, 11% | TTP |
| Pawlik et al. [33] | 57 | No | Sorafenib + DEB-TACE | Continuous | B, 34% C, 64% | A, 89% B, 11% | Tumor response |
| Cabrera et al. [34] | 47 | No | Sorafenib + DEB-TACE or Y-90 | Continuous | B, 81% C, 19% | A, 72% B, 28% | Tumor response |
| Chaudhury et al. [35] | 21 | No | Sorafenib + Y-90 | Continuous | A, 71% B, 24% | Tumor response |
NA = not available.